Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation

Oncogene

Volumn 32, Issue 36, 2013, Pages 4264-4272

  Peyre, M ^a,b,c   Stemmer Rachamimov, A ^d   Clermont Taranchon, E ^b,c   Quentin, S ^e   El Taraya, N ^e,f   Walczak, C ^e,f   Volk, A ^e,f   Niwa Kawakita, M ^b,c   Karboul, N ^b,c   Giovannini, M ^g   Kalamarides, M ^a,b,c  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Université Paris 13   (France)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e INSERM   (France)

^f INSTITUT CURIE   (France)

^g HOUSE RESEARCH INSTITUTE   (United States)

Author keywords

adenovirus; CDKN2AB; meningioma; mouse model; NF2

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2AB; PROTEIN; PROTEIN NF2; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CANCER INCIDENCE; CELL CULTURE; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE DELETION; HETEROZYGOTE; HOMOZYGOTE; IN VITRO STUDY; MENINGIOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POINT MUTATION; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; CELL AGING; CHROMOSOME ABERRATIONS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC LOCI; GENOTYPE; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, KNOCKOUT; NEOPLASM GRADING; NEUROFIBROMIN 2; OPTICAL IMAGING; PHENOTYPE; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; MUS;

EID: 84883741416     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.436     Document Type: Article

References (41)

1. Louis D, Ohgaki H, Wiestler O, Cavenee W. WHO Classification of Tumours of the Central Nervous System. 4th edn. IRAC Press: Lyon, 2007.
2. Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 2009; 64: 56-60, discussion.
3. Hanft S, Canoll P, Bruce JN. A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol. 2010; 99: 433-443.
4. Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestana A et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999; 18: 2231-2239.
5. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006; 5: 1045-1054.
6. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994; 6: 180-184.
7. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 2004; 101: 210-218.
8. Buschges R, Ichimura K, Weber RG, Reifenberger G, Collins VP. Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 2002; 12: 145-153.
9. Lamszus K, Vahldiek F, Mautner VF, Schichor C, Tonn J, Stavrou D et al. Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 2000; 59: 504-512.
10. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Callaghan R, Collado M, Roldan P et al. Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 2004; 148: 123-128.
11. Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 1997; 14: 611-616.
12. Mihaila D, Jankowski M, Gutierrez JA, Rosenblum ML, Newsham IF, Bogler O et al. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 2003; 9: 4443-4451.
13. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 2010; 16: 4155-4164.
14. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-275.
15. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene 2004; 23: 379-385.
16. Krimpenfort P, Ijpenberg A, Song JY, van der Valk M, Nawijn M, Zevenhoven J et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007; 448: 943-946.
17. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 2001; 159: 661-669.
18. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997; 94: 14719-14724.
19. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 2002; 12: 183-190.
20. Korshunov A, Shishkina L, Golanov A. Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. Int J Cancer 2003; 104: 728-734.
21. Ragel BT, Couldwell WT, Gillespie DL, Wendland MM, Whang K, Jensen RL. A comparison of the cell lines used in meningioma research. Surg Neurol 2008; 70: 295-307, discussion.
22. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999; 59: 2217-2222.
23. Morrison JP, Satoh H, Foley J, Horton JL, Dunnick JK, Kissling GE et al. N-ethyl-Nnitrosourea (ENU)-induced meningiomatosis and meningioma in p16(INK4a)/p19(ARF) tumor suppressor gene-deficient mice. Toxicol Pathol 2007; 35: 780-787.
24. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002; 16: 1060-1065.
25. Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M et al. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol 2008; 18: 62-70.
26. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-57.
27. James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V et al. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis 2008; 29: 278-292.
28. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008; 13: 261-271.
29. Lyons SK, Meuwissen R, Krimpenfort P, Berns A. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res 2003; 63: 7042-7046.
30. Pistolesi S, Boldrini L, Gisfredi S, De Ieso K, Camacci T, Caniglia M et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol 2004; 30: 118-125.
31. Vautier J, Heilmann M, Walczak C, Mispelter J, Volk A. 2D and 3D radial multigradient-echo DCE MRI in murine tumor models with dynamic R2-corrected R1 mapping. Magn Reson Med 2010; 64: 313-318.
32. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43: 289-294.
33. Sotillo R, Schvartzman JM, Benezra R. Very CIN-ful: whole chromosome instability promotes tumor suppressor loss of heterozygosity. Cancer Cell 2009; 16: 451-452.
34. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436: 642.
35. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, Bostrom J et al. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 2001; 55: 149-158.
36. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011; 30: 2087-2097.
37. Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U. Bevacizumabinduced regression of anaplastic meningioma. Ann Oncol 2010; 21: 2445-2446.
38. Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011; 22: 990-991.
39. Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012; 109: 63-70.
40. Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D et al. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. Neoplasia 2012; 14: 54-64.
41. Gaya A, Daley F, Taylor NJ, Tozer G, Qureshi U, Padhani A et al. Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study. Br J Cancer 2008; 99: 321-326.